Microbiotica Shortlisted for 2017 OBN Awards ‘Best Start-up Biotech Company’

04:14 EDT 9 Aug 2017 | Instinctif Partners

Cambridge, UK, 9 August 2017 - Microbiotica, a leading player in microbiome-based therapeutics, is delighted to be announced that it has been selected as a finalist in the ‘Best Start-up Biotech Company’ category of the OBN Awards 2017.

Being selected for the shortlist recognises Microbiotica’s commercial potential in the fast growing microbiome space, reflecting its innovative understanding of the gut microbiome and the therapeutic potential to address a host of disorders through microbial targets.
In 2016, Microbiotica was created with £8m funding from Cambridge Innovation Capital and IP Group to commercialise the groundbreaking research of the Wellcome Trust Sanger Insititute.

The finalist will be selected on the following criteria: formed for less than two years, has raised substantial financial support (£1m-£20m), is developing novel and disruptive products and has proof of financing raised and ongoing deals in the pipeline, with evidence of a commercialisation strategy.

The winners for all eight categories will be announced at the awards evening on Tuesday 5 October 2017 at the OBN Annual Awards Ceremony at Oxford Town Hall.

About Microbiotica

  • Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute.
  • Microbiotica’s founders are Mike Romanos, Trevor Lawley and Gordon Dougan, FRS.
  • CIC and IP Group are co-investors in Microbiotica, with a £4m contribution from each party to provide total initial funding of £8m.
  • Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute.

About the Microbiome

Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.


For further information please contact: Microbiotica Rowena Gardner +44 1223 786063 / +44 7801 480569 Instinctif Partners (for media enquiries): Sue Charles/Gemma Harris +44 20 7866 7860 NEXT ARTICLE

More From BioPortfolio on "Microbiotica Shortlisted for 2017 OBN Awards ‘Best Start-up Biotech Company’ "

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...